Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: A retrospective, observational study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 957-962

  Morgan, C Ll ^a   Mukherjee, J ^b   Jenkins Jones, S ^a   Holden, S E ^a,c   Currie, Craig J ^a,c  

^a Global Epidemiology   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

First line therapy; MACE; Metformin; Mortality; Myocardial infarction; Stroke; Sulphonylurea

Indexed keywords

CREATININE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; TOLBUTAMIDE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; ICD-10; ICD-9; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTRAINDICATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; STROKE; UNITED KINGDOM;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; SULFONYLUREA COMPOUNDS;

EID: 84912100243     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12302     Document Type: Article

References (26)

1. Diabetes UK. Diabetes in the UK 2011/2012: Key Statistics on Diabetes. London: Diabetes UK 2011. Available from URL: http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK- 2011-12.pdf. Accessed 7 February 2014.
2. The National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: The Management of Type 2 Diabetes (Update) (CG66). London: Royal College of Physicians 2008. Available from URL: http://guidance.nice.org.uk/CG66. Accessed 7 February 2014.
3. Desai NR, Shrank WH, Fischer MA et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012; 125: 302.e1-302.e7.
4. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169-174.
5. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
6. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
8. Wheeler S, Moore K, Forsberg CW et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013; 56: 1934-1943.
9. Roumie CL, Hung AM, Greevy RA. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157: 601-610.
10. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
11. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013; 30: 1160-1171.
12. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with noninsulin- dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
13. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598-3604.
14. Kahn SE, Haffner SM, Heisse MA, Herman WH, Holman RR. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
16. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mildto- moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437.
17. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001; 18: 483-488.
18. Kajbaf F, Arnouts P, de Broe M, Lalau J-D. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf 2013; 22: 1027-1035.
19. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
20. Zoungas S, Patel A, Chalmers J et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418.
21. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012; 14: 424-432.
22. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited Circulation 1997; 96: 29-32.
23. Soranna D, Scotti L, Zambon A et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822.
24. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
25. Roussel R, Travert F, Pasquet B et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899.
26. Holden SE, Currie CJ. Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab 2014; 16: 885-890.